Video

Helping Manage the Cost of Cancer with a Patient Lens: Opportunities for Pharmacists

This webcast discusses opportunities for pharmacists to address the cost of cancer care and enable improved access and outcomes for patients. During the webcast, a panel of experts discusses how pharmacists can help minimize costs associated with cancer therapy, including treatment and clinical practice considerations, as well as more direct financial support that can help ensure access to effective therapies for patients. Additional Resource Guide can be found here: https://www.pharmacytimes.com/view/managing-cancer-cost-resource-guide.

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously
Related Content
Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma
December 20th 2024

Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma

George DeMaagd, PharmD, BCPS Gregory Franz, MD, MPH Zachery Halford, PharmD, BCOP, BCPPS
Site Logo
December 20th 2024

Examining the 505(b)(2) Pathway and Implementation into EHR

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Depiction of colorectal cancer tumor growth Image Credit: © Dr_Microbe - stock.adobe.com
December 18th 2024

Chronic Inflammation Driven by Diet May Contribute to Colorectal Cancer, Study Finds

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Small Cell Lung Cancer Cells: These small, round cells in the lungs divide rapidly and are known for early metastasis, resulting in highly aggressive cancer.
December 17th 2024

Sacituzumab Govitecan-hziy Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Treatment

Luke Halpern, Assistant Editor
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com
December 16th 2024

FDA Approves Cosibelimab-Ipdl for Adult Patients with mCSCC or laCSCC

Gillian McGovern, Assistant Editor